Do analysts recommend SIGA or DWTX?

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 552.17%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor SIGA or DWTX?

In the previous week, Siga Technologies had 3 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 6 mentions for Siga Technologies and 3 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.28 beat Siga Technologies' score of 0.22 indicating that Dogwood Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ANTX or DWTX?

Anthem is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.10 N/A Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A

Is ANTX or DWTX more profitable?

Anthem's return on equity of -52.35% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -52.35% -47.25% Dogwood Therapeutics N/A -108.57% -30.28%

Does the media favor ACOG or DWTX?

In the previous week, Alpha Cognition and Alpha Cognition both had 3 articles in the media. Alpha Cognition's average media sentiment score of 0.37 beat Dogwood Therapeutics' score of 0.28 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate DWTX or SBTX?

Dogwood Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 552.17%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dogwood Therapeutics is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, DWTX or SBTX?

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is DWTX or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% Silverback Therapeutics N/A -29.62% -28.20%

Dogwood Therapeutics (DWTX) Competitors

$1.84 +0.01 (+0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$1.83 -0.01 (-0.76%)

As of 06:22 PM Eastern

Compare

DWTX vs. SLGL, SIGA, ANTX, ACOG, and SBTX

Should you buy Dogwood Therapeutics stock or one of its competitors? Dogwood Therapeutics's main competitors and comparable companies include Sol-Gel Technologies (SLGL), Siga Technologies (SIGA), Anthem (ANTX), Alpha Cognition (ACOG), and Silverback Therapeutics (SBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dogwood Therapeutics compare to Sol-Gel Technologies?

Dogwood Therapeutics (NASDAQ:DWTX) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 1 mentions for Sol-Gel Technologies. Dogwood Therapeutics' average media sentiment score of 0.28 beat Sol-Gel Technologies' score of 0.00 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Dogwood Therapeutics	Neutral
Sol-Gel Technologies	Neutral

Sol-Gel Technologies has higher revenue and earnings than Dogwood Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Sol-Gel Technologies	$19.39M	11.29	-$6.13M	-$0.34	N/A

Dogwood Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 552.17%. Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 153.47%. Given Dogwood Therapeutics' higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Dogwood Therapeutics has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Dogwood Therapeutics has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

Summary

Sol-Gel Technologies beats Dogwood Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Dogwood Therapeutics has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. Siga Technologies' return on equity of -1.51% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.51%	-1.25%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

In the previous week, Siga Technologies had 3 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 6 mentions for Siga Technologies and 3 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.28 beat Siga Technologies' score of 0.22 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 552.17%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Siga Technologies has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.71, suggesting that its stock price is 71% more volatile than the broader market.

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 2.7% of Siga Technologies shares are held by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Siga Technologies has higher revenue and earnings than Dogwood Therapeutics. Siga Technologies is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.19	$23.28M	-$0.05	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Summary

Siga Technologies beats Dogwood Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Anthem?

Anthem (NASDAQ:ANTX) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Anthem has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market.

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Anthem. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 2 mentions for Anthem. Dogwood Therapeutics' average media sentiment score of 0.28 beat Anthem's score of 0.00 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anthem	Neutral
Dogwood Therapeutics	Neutral

Anthem presently has a consensus price target of $9.00, suggesting a potential upside of 53.32%. Dogwood Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 552.17%. Given Dogwood Therapeutics' higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

90.5% of Anthem shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 22.6% of Anthem shares are held by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Anthem's return on equity of -52.35% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Anthem is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Summary

Dogwood Therapeutics beats Anthem on 7 of the 13 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Alpha Cognition presently has a consensus target price of $16.00, suggesting a potential upside of 79.98%. Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 552.17%. Given Dogwood Therapeutics' higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alpha Cognition has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market.

In the previous week, Alpha Cognition and Alpha Cognition both had 3 articles in the media. Alpha Cognition's average media sentiment score of 0.37 beat Dogwood Therapeutics' score of 0.28 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Cognition has higher revenue and earnings than Dogwood Therapeutics. Alpha Cognition is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	18.94	-$20.67M	-$1.35	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

9.1% of Dogwood Therapeutics shares are held by institutional investors. 8.6% of Alpha Cognition shares are held by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Dogwood Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Alpha Cognition's return on equity of -58.35% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Summary

Alpha Cognition beats Dogwood Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Silverback Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Dogwood Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 552.17%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Dogwood Therapeutics is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dogwood Therapeutics has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Silverback Therapeutics' return on equity of -29.62% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
Silverback Therapeutics	N/A	-29.62%	-28.20%

9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Dogwood Therapeutics had 3 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 0 mentions for Silverback Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.28 beat Silverback Therapeutics' score of 0.00 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Dogwood Therapeutics	Neutral
Silverback Therapeutics	Neutral

Summary

Dogwood Therapeutics beats Silverback Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Dogwood Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DWTX vs. The Competition

Export

Metric	Dogwood Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$61.54M	$12.02B	$7.09B	$12.96B
Dividend Yield	N/A	2.69%	2.57%	10.34%
P/E Ratio	-0.17	783.52	268.15	25.04
Price / Sales	N/A	738.50	584.49	84.26
Price / Cash	N/A	70.00	72.26	50.42
Price / Book	0.79	10.56	13.21	6.18
Net Income	-$34.26M	$2.78B	$3.44B	$347.05M
7 Day Performance	2.79%	0.89%	2.27%	0.99%
1 Month Performance	29.58%	-1.48%	-0.23%	-0.64%
1 Year Performance	-61.43%	182.35%	76.15%	22.27%

Dogwood Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DWTX Dogwood Therapeutics	2.4119 of 5 stars	$1.84 +0.5%	$12.00 +552.2%	-62.1%	$61.54M	N/A	N/A	5	News Coverage Upcoming Earnings
SLGL Sol-Gel Technologies	3.2679 of 5 stars	$84.28 -0.3%	$197.50 +134.4%	+430.0%	$236.81M	$19.39M	N/A	50
SIGA Siga Technologies	0.8082 of 5 stars	$3.24 +0.9%	N/A	-67.3%	$232.37M	$94.57M	12.00	40	Earnings Report
ANTX Anthem	1.8522 of 5 stars	$5.95 +0.2%	$9.00 +51.3%	+452.3%	$214.32M	N/A	N/A	N/A	Earnings Report
ACOG Alpha Cognition	4.4289 of 5 stars	$9.14 +2.2%	$16.00 +75.1%	-10.2%	$198.89M	$10.22M	N/A	N/A	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DWTX) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. SLGL, SIGA, ANTX, ACOG, and SBTX

How does Dogwood Therapeutics compare to Sol-Gel Technologies?

Summary

How does Dogwood Therapeutics compare to Siga Technologies?

Summary

How does Dogwood Therapeutics compare to Anthem?

Summary

How does Dogwood Therapeutics compare to Alpha Cognition?

Summary

How does Dogwood Therapeutics compare to Silverback Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. SLGL, SIGA, ANTX, ACOG, and SBTX

How does Dogwood Therapeutics compare to Sol-Gel Technologies?

Does the media prefer DWTX or SLGL?

Which has better earnings & valuation, DWTX or SLGL?

Do analysts rate DWTX or SLGL?

Do insiders and institutionals have more ownership in DWTX or SLGL?

Which has more risk and volatility, DWTX or SLGL?

Is DWTX or SLGL more profitable?

Summary

How does Dogwood Therapeutics compare to Siga Technologies?

Is SIGA or DWTX more profitable?

Does the media favor SIGA or DWTX?

Do analysts recommend SIGA or DWTX?

Which has more risk & volatility, SIGA or DWTX?

Do institutionals & insiders believe in SIGA or DWTX?

Which has better valuation & earnings, SIGA or DWTX?

Summary

How does Dogwood Therapeutics compare to Anthem?

Which has more risk & volatility, ANTX or DWTX?

Does the media favor ANTX or DWTX?

Do analysts prefer ANTX or DWTX?

Do insiders and institutionals have more ownership in ANTX or DWTX?

Is ANTX or DWTX more profitable?

Which has better earnings and valuation, ANTX or DWTX?

Summary

How does Dogwood Therapeutics compare to Alpha Cognition?

Do analysts recommend ACOG or DWTX?

Which has more volatility and risk, ACOG or DWTX?

Does the media favor ACOG or DWTX?

Which has higher valuation & earnings, ACOG or DWTX?

Do insiders & institutionals have more ownership in ACOG or DWTX?

Is ACOG or DWTX more profitable?

Summary

How does Dogwood Therapeutics compare to Silverback Therapeutics?

Do analysts rate DWTX or SBTX?

Which has more volatility and risk, DWTX or SBTX?

Which has stronger valuation and earnings, DWTX or SBTX?

Is DWTX or SBTX more profitable?

Do insiders and institutionals believe in DWTX or SBTX?

Does the media refer more to DWTX or SBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools